Established and new mouse models reveal E2f1 and Cdk2 dependency of retinoblastoma, and expose effective strategies to block tumor initiation

Oncogene

Volumn 31, Issue 48, 2012, Pages 5019-5028

  Sangwan, M ^a   McCurdy, S R ^a   Livne Bar, I ^a   Ahmad, M ^a   Wrana, J L ^b   Chen, D ^a   Bremner, R ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Cdk; chemoprevention; E2f; p107; retinoblastoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; HLM 006474; PROTEIN P107; PROTEIN P27; R 547; RETINOBLASTOMA PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR E2F2; TRANSCRIPTION FACTOR E2F3; UNCLASSIFIED DRUG;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL DIVISION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; FEMALE; FETUS; GENE DELETION; GENE EXPRESSION; GENE LOSS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; RETINOBLASTOMA; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

ANIMALS; CYCLIN-DEPENDENT KINASE 2; DISEASE MODELS, ANIMAL; E2F1 TRANSCRIPTION FACTOR; MICE; MICE, KNOCKOUT; RETINOBLASTOMA; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

MUS;

EID: 84870542355     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.654     Document Type: Article

References (53)

1. Cobrinik D. Pocket proteins and cell cycle control. Oncogene 2005; 24: 2796-2809. (Pubitemid 40638091)
2. Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene 2005; 24: 2810-2826. (Pubitemid 40638092)
3. Chen D, Pacal M, Wenzel PL, Knoepfler PS, Leone G, Bremner R. Division and apoptosis of E2f-deficient retinal progenitors. Nature 2009; 462: 925.
4. Chong JL, Wenzel PL, Saenz-Robles MT, Nair V, Ferrey A, Hagan JP et al. E2f1-3 switch from activators in progenitor cells to repressors in differentiating cells. Nature 2009; 462: 930-934.
5. Chen D, Opavsky R, Pacal M, Tanimoto N, Wenzel P, Seeliger MW et al. Rb- Mediated Neuronal Differentiation through Cell-Cycle-Independent Regulation of E2f3a. PLoS Biol 2007; 5: e179.
6. Tsai KY, Hu Y, Macleod KF, Crowley D, Yamasaki L, Jacks T. Mutation of E2f-1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rbdeficient mouse embryos. Mol Cell 1998; 2: 293-304. (Pubitemid 128379270)
7. Ziebold U, Reza T, Caron A, Lees JA. E2F3 contributes both to the inappropriate proliferation and to the apoptosis arising in Rb mutant embryos. Genes Dev 2001; 15: 386-391. (Pubitemid 32186999)
8. McClellan KA, Ruzhynsky VA, Douda DN, Vanderluit JL, Ferguson KL, Chen D et al. Unique requirement for Rb/E2F3 in neuronal migration: evidence for cell cycleindependent functions. Mol Cell Biol 2007; 27: 4825-4843. (Pubitemid 47016135)
9. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9: 153-166.
10. Binne UK, Classon MK, Dick FA, Wei W, Rape M, Kaelin Jr WG et al. Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nat Cell Biol 2007; 9: 225-232. (Pubitemid 46420866)
11. Ji P, Jiang H, Rekhtman K, Bloom J, Ichetovkin M, Pagano M et al. An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partialpenetrance Rb mutant. Mol Cell 2004; 16: 47-58. (Pubitemid 39330151)
12. Wang H, Bauzon F, Ji P, Xu X, Sun D, Locker J et al. Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/ mice. Nat Genet 2010; 42: 83-88.
13. Rodier G, Makris C, Coulombe P, Scime A, Nakayama K, Nakayama KI et al. p107 inhibits G1 to S phase progression by down-regulating expression of the F-box protein Skp2. J Cell Biol 2005; 168: 55-66. (Pubitemid 40111057)
14. Castano E, Kleyner Y, Dynlacht BD. Dual cyclin-binding domains are required for p107 to function as a kinase inhibitor. Mol Cell Biol 1998; 18: 5380-5391. (Pubitemid 28388121)
15. Chibazakura T, McGrew SG, Cooper JA, Yoshikawa H, Roberts JM. Regulation of cyclin-dependent kinase activity during mitotic exit and maintenance of genome stability by p21, p27, and p107. Proc Natl Acad Sci USA 2004; 101: 4465-4470. (Pubitemid 38437434)
16. Balmer A, Zografos L, Munier F. Diagnosis and current management of retinoblastoma. Oncogene 2006; 25: 5341-5349. (Pubitemid 44299096)
17. Robanus-Maandag E, Dekker M, van der Valk M, Carrozza ML, Jeanny JC, Dannenberg JH et al. p107 is a suppressor of retinoblastoma development in pRbdeficient mice. Genes Dev 1998; 12: 1599-1609. (Pubitemid 28299512)
18. Chen D, Livne-Bar I, Vanderluit JL, Slack RS, Agochiya M, Bremner R. Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma. Cancer Cell 2004; 5: 539-551. (Pubitemid 38748916)
19. MacPherson D, Sage J, Kim T, Ho D, McLaughlin ME, Jacks T. Cell type-specific effects of Rb deletion in the murine retina. Genes Dev 2004; 18: 1681-1694. (Pubitemid 38938185)
20. Dannenberg JH, Schuijff L, Dekker M, van der Valk M, te Riele H. Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130. Genes Dev 2004; 18: 2952-2962. (Pubitemid 39602313)
21. Zhang J, Schweers B, Dyer MA. The First Knockout Mouse Model of Retinoblastoma. Cell Cycle 2004; 3: 952-959. (Pubitemid 40185382)
22. Lara MF, Garcia-Escudero R, Ruiz S, Santos M, Moral M, Martinez-Cruz AB et al. Gene profiling approaches help to define the specific functions of retinoblastoma family in epidermis. Mol Carcinog 2008; 47: 209-221. (Pubitemid 351398064)
23. Lara MF, Santos M, Ruiz S, Segrelles C, Moral M, Martinez-Cruz AB et al. p107 acts as a tumor suppressor in pRb-deficient epidermis. Mol Carcinog 2008; 47: 105-113. (Pubitemid 351231439)
24. Hurford Jr RK, Cobrinik D, Lee MH, Dyson N. pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes Dev 1997; 11: 1447-1463. (Pubitemid 27259855)
25. Black EP, Huang E, Dressman H, Rempel R, Laakso N, Asa SL et al. Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Res 2003; 63: 3716-3723. (Pubitemid 36793057)
26. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8: 253-267. (Pubitemid 351430863)
27. Besson A, Hwang HC, Cicero S, Donovan SL, Gurian-West M, Johnson D et al. Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev 2007; 21: 1731-1746. (Pubitemid 47076473)
28. Santamaria D, Barriere C, Cerqueira A, Hunt S, Tardy C, Newton K et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007; 448: 811-815. (Pubitemid 47266342)
29. DePinto W, Chu XJ, Yin X, Smith M, Packman K, Goelzer P et al. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol Cancer Ther 2006; 5: 2644-2658. (Pubitemid 44848991)
30. Malumbres M, Pevarello P, Barbacid M, Bischoff Jr. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 2008; 29: 16-21.
31. Bandara LR, Girling R, La Thangue NB. Apoptosis induced in mammalian cells by small peptides that functionally antagonize the Rb-regulated E2F transcription factor. Nat Biotechnol 1997; 15: 896-901.
32. Fabbrizio E, Le Cam L, Polanowska J, Kaczorek M, Lamb N, Brent R et al. Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity. Oncogene 1999; 18: 4357-4363. (Pubitemid 29392376)
33. Montigiani S, Muller R, Kontermann RE. Inhibition of cell proliferation and induction of apoptosis by novel tetravalent peptides inhibiting DNA binding of E2F. Oncogene 2003; 22: 4943-4952. (Pubitemid 37026393)
34. Ma Y, Kurtyka CA, Boyapalle S, Sung SS, Lawrence H, Guida W et al. A smallmolecule E2F inhibitor blocks growth in a melanoma culture model. Cancer Res 2008; 68: 6292-6299.
35. Classon M, Salama S, Gorka C, Mulloy R, Braun P, Harlow E. Combinatorial roles for pRB, p107, and p130 in E2F-mediated cell cycle control. Proc Natl Acad Sci USA 2000; 97: 10820-10825.
36. Chicas A, Wang X, Zhang C, McCurrach M, Zhao Z, Mert O et al. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell 2010; 17: 376-387.
37. Xu M, Sheppard KA, Peng CY, Yee AS, Piwnica-Worms H. Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol Cell Biol 1994; 14: 8420-8431. (Pubitemid 24373591)
38. Dynlacht BD, Flores O, Lees JA, Harlow E. Differential regulation of E2F transactivation by cyclin/cdk2 complexes. Genes Dev 1994; 8: 1772-1786. (Pubitemid 24265784)
39. Lee EY, Cam H, Ziebold U, Rayman JB, Lees JA, Dynlacht BD. E2F4 loss suppresses tumorigenesis in Rb mutant mice. Cancer Cell 2002; 2: 463-472. (Pubitemid 41043951)
40. Brugarolas J, Bronson RT, Jacks T. p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells. J Cell Biol 1998; 141: 503-514. (Pubitemid 28237097)
41. Park MS, Rosai J, Nguyen HT, Capodieci P, Cordon-Cardo C, Koff A. p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc Natl Acad Sci USA 1999; 96: 6382-6387. (Pubitemid 29256674)
42. Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S et al. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 1998; 12: 2899-2911. (Pubitemid 28440148)
43. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation in the mouse. Nature 1992; 359: 295-300.
44. Buttitta LA, Katzaroff AJ, Perez CL, de la Cruz A, Edgar BA. A double-assurance mechanism controls cell cycle exit upon terminal differentiation in Drosophila. Dev Cell 2007; 12: 631-643. (Pubitemid 46523642)
45. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward. Clin Cancer Res 2006; 12: 3661-3697. (Pubitemid 44000248)
46. Lindor NM, McMaster ML, Lindor CJ, Greene MH. Concise handbook of familial cancer susceptibility syndromes - second edition. J Natl Cancer Inst Monogr 2008; 38: 1-93.
47. Ng AK, Kenney LB, Gilbert ES, Travis LB. Secondary malignancies across the age spectrum. Semin Radiat Oncol 2010; 20: 67-78.
48. Yu CL, Tucker MA, Abramson DH, Furukawa K, Seddon JM, Stovall M et al. Causespecific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst 2009; 101: 581-591.
49. Padmakumar VC, Aleem E, Berthet C, Hilton MB, Kaldis P. Cdk2 and Cdk4 activities are dispensable for tumorigenesis caused by the loss of p53. Mol Cell Biol 2009; 29: 2582-2593.
50. Martin A, Odajima J, Hunt SL, Dubus P, Ortega S, Malumbres M et al. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell 2005; 7: 591-598. (Pubitemid 40799251)
51. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003; 3: 233-245. (Pubitemid 37443879)
52. Boquoi A, Chen T, Enders GH. Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032. Cancer Prev Res (Phila) 2009; 2: 800-806.
53. Conkrite K, Sundby M, Mukai S, Thomson JM, Mu D, Hammond SM et al. miR- 17B92 cooperates with RB pathway mutations to promote retinoblastoma. Genes Dev 2011; 25: 1734-1745.